Neuralstem (NASDAQ:CUR) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Wednesday.
Shares of CUR traded up $0.01 during mid-day trading on Wednesday, hitting $0.57. 150,500 shares of the company’s stock were exchanged, compared to its average volume of 178,473. Neuralstem has a fifty-two week low of $0.52 and a fifty-two week high of $3.09.
Neuralstem (NASDAQ:CUR) last announced its earnings results on Wednesday, August 15th. The company reported ($0.04) earnings per share for the quarter. Neuralstem had a negative return on equity of 75.90% and a negative net margin of 1,401.80%. The business had revenue of $0.25 million for the quarter.
Neuralstem, Inc, a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types.
Read More: Leveraged Buyout (LBO)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.